Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAP-IT: Azenosertib + Carboplatin + Pembrolizumab in Metastatic TNBC
NCT06351332Phase 1Terminated
- Sponsor
- Filipa Lynce
- Start
- May 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azenosertib in triple-negative breast cancer (TNBC), sponsored by Filipa Lynce. Primary endpoints: Dose Limiting Toxicity at 3 weeks, Maximum Tolerated Dose at 3 weeks and 1 more. Started May 2024; status: terminated.
02
Drugs
azenosertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06351332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351332.